BRAF and lung cancer: Whilst we are not aware of any data that interrogates pathway reactivation upon BRAF inhibition in BRAF mutant lung cancer models, pathway reactivation after KRAS G12C inhibition in G12C mutant lung cancer has been analysed [15].